Does dapagliflozin reduce the no-reflow phenomenon in patients with T2DM and AMI undergoing PCI?
Prior long-term use of dapagliflozin is associated with a reduced incidence of the angiographic no-reflow phenomenon in patients with T2DM undergoing PCI for acute myocardial infarction.
OBJECTIVE: This study aimed to assess the effect of dapagliflozin on the no-reflow phenomenon in patients with type II diabetes mellitus (T2DM) and acute myocardial infarction (AMI) who underwent percutaneous coronary intervention (PCI). METHODS: This single-center, observational cohort study included a total of 829 consecutive T2DM patients who were diagnosed with AMI and underwent PCI within 24 h of the onset of symptoms. Only patients using dapagliflozin (10 mg per day) for more than one year were considered as patients using dapagliflozin. The no-reflow phenomenon was defined as inadequate myocardial perfusion within a segment of the coronary circulation without angiographic evidence of mechanical vessel obstruction, dissection, or residual stenosis after PCI. RESULTS: = 0.043) was the only independent predictor of the no-reflow phenomenon in NSTEMI. CONCLUSION: Lower rates of the no-reflow phenomenon were observed in T2DM patients taking dapagliflozin, diagnosed with AMI, and underwent PCI. However, this finding requires further investigation.
Quisi et al. (Mon,) studied this question.